# Selenium Thyroid Autoimmunity Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/selenium-thyroid-autoimmunity-meta-analysis-evidence-review
Category: evidence-review
Summary: Selenium Thyroid Autoimmunity Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass
Last reviewed: 2026-06-15
Reviewed by: Migaku Evidence Review
# Selenium Thyroid Autoimmunity Meta-analysis: What the Evidence Says

## Quick Answer

Selenium Thyroid Autoimmunity Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Myo-Inositol Plus Selenium vs. Selenium Alone in Hashimoto’s Thyroiditis with Subclinical Hypothyroidism: A Systematic Review and Updated Meta-Analysis with Trial Sequential Analysis | systematic review | 1 | 2026-04-22 | 10.3390/jcm15093179 |
| Beyond levothyroxine: a narrative review of adjunctive management strategies for Hashimoto’s thyroiditis | preclinical study | 4 | 2026-04-24 | 10.21037/gs-2025-1-554 |

## What The Sources Report

- Subclinical hypothyroidism has been associated with metabolic disturbances, increased cardiovascular risk, and reduced quality of life, highlighting the need for effective management strategies. [Stanchev Pavel (2026); evidence level 1]
- It is thought to enhance TSH signaling and support thyroid hormone synthesis, with emerging clinical evidence suggesting a beneficial effect on thyroid function parameters. [Stanchev Pavel (2026); evidence level 1]
- It is associated with elevated anti-thyroid peroxidase antibodies (TPOAb) and often anti-thyroglobulin antibodies (TgAb). [Personius Lydia (2026); evidence level 4]
- The incidence of HT has increased over recent decades and is higher with advancing age, in women, and in iodine-sufficient populations. [Personius Lydia (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For selenium thyroid autoimmunity meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Stanchev Pavel (2026). Myo-Inositol Plus Selenium vs. Selenium Alone in Hashimoto’s Thyroiditis with Subclinical Hypothyroidism: A Systematic Review and Updated Meta-Analysis with Trial Sequential Analysis. DOI: 10.3390/jcm15093179. PMCID: PMC13164135. PMID: 42122912. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13164135/
- Personius Lydia (2026). Beyond levothyroxine: a narrative review of adjunctive management strategies for Hashimoto’s thyroiditis. DOI: 10.21037/gs-2025-1-554. PMCID: PMC13184362. PMID: 42164686. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13184362/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.